Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib

Open access
Bauer, Sebastian, Hartmann, Jörg Thomas, de Wit, Maike, Lang, Hauke, Grabellus, Florian, Antoch, Gerald, Niebel, Wolfgang, Erhard, Jochen, Ebeling, Peter, Zeth, Matthias, Taeger, Georg, Seeber, Siegfried, Flasshove, Michael, Schütte, Jochen · 2005 · International Journal of Cancer

Abstract

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Long‐term survival of patients with metastatic disease has only been observed in patients with completely resected disease. Recently, the tyrosine kinase inhibitor imatinib has been found to yield responses in the majority of patients with metastatic GIST suggesting improved resectability in responding patients. Combined treatment approaches including resective surgery after imatinib treatment in patients with advanced metastatic disease have rarely been explored. We report a series of 90 patients with metastatic GIST in whom treatment with imatinib enabled 12 patients with mostly recurrent and extensive disease to be considered for resection of residual disease. In 11 of these patients, complete resection could be achieved. Viable tumor cells were found in all but one resected specimens suggesting that despite favorable radiological or clinical responses, imatinib is unlikely to induce pathological complete responses. Until more mature data from prospective trials are available, these data suggest that an early aggressive surgical approach should be considered for all patients with metastatic GIST. Further trials investigating a combined surgical and pre/postoperative treatment with imatinib in patients with advanced metastatic GIST are warranted. © 2005 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.21164

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 173

Metadata

Authors
Bauer, S., Hartmann, J. T., de Wit, M., Lang, H., Grabellus, F., Antoch, G., Niebel, W., Erhard, J., Ebeling, P., Zeth, M., Taeger, G., Seeber, S., Flasshove, M., & Schütte, J.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2005-08-16
Volume
117
Issue
2
Pages
316-325
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2001967800
Cited by
173
References
2
FWCI
11.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. https://app.cochat.ai/papers/10.1002/ijc.21164
The paper
Bauer, S., Hartmann, J. T., de Wit, M., Lang, H., Grabellus, F., Antoch, G., Niebel, W., Erhard, J., Ebeling, P., Zeth, M., Taeger, G., Seeber, S., Flasshove, M., & Schütte, J. (2005). Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. International Journal of Cancer. https://doi.org/10.1002/ijc.21164

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.